Vasopressin antagonists in the management of heart failure

Joseph Rossi*, Cesare Orlandi, Mihai Gheorghiade

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Vasopressin antagonists have been studied in a variety of clinical settings, including patients with acute and chronic heart failure. The clinical trials published to date have sought to describe the clinical and physiologic effects of these agents in an effort to prove clinical efficacy and safety. A variety of agents with varying effects on V2 and V1a vasopressin receptor subtype have been studied. They have been shown to reduce bodyweight and improve serum sodium without worsening renal function. They may also decrease the need for loop diuretic use and may be particularly useful in patients with hyponatremia in the setting of volume overload. Further studies are underway that are powered to assess for morbidity and mortality benefits. The beneficial effects have been well documented but, until outcomes are understood more fully, the use of these agents should be limited to currently approved indications. In the USA, this includes only the treatment of euvolemic hyponatremia.

Original languageEnglish (US)
Pages (from-to)323-330
Number of pages8
JournalExpert Review of Cardiovascular Therapy
Issue number2
StatePublished - Mar 1 2007


  • Bodyweight
  • Cardiac failure
  • Diuretics
  • Hyponatremia
  • Tolvaptan
  • Vasopressin antagonist

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Vasopressin antagonists in the management of heart failure'. Together they form a unique fingerprint.

Cite this